MT1980: translating anti-inflammatory and metabolic mechanisms into new treatment opportunities for schizophrenia

Background

Neuroinflammation contributes to schizophrenia pathophysiology in up to 50% of patients and is associated with persistent negative symptoms, including anhedonia, avolition, and social withdrawal. These symptoms are among the strongest predictors of long-term disability and remain a major unmet clinical need. Currently available antipsychotics have limited efficacy for negative symptoms while contributing to cardiometabolic morbidity and a 10–20 year reduction in life expectancy.

Low-grade peripheral inflammation, reflected by elevated biomarkers such as IL-6 and CRP, is present in a substantial subgroup of patients, including drug-naïve individuals, and is associated with symptom severity. Longitudinal and genetic evidence further implicates immune pathways in disease onset and progression. Mechanistically, inflammatory activation of the kynurenine pathway may disrupt dopaminergic and glutamatergic signalling, both central to negative symptom biology.

Recent immunomodulatory trials enriched for patients with elevated inflammatory markers have shown improved outcomes, supporting inflammation as a therapeutic target. However, current anti-inflammatory and biologic approaches are limited by poor central nervous system penetration, incomplete mechanistic targeting, and practical and economic barriers to large-scale use.

MT1980 is a re-formulated, brain-penetrant PPAR-α agonist with additional anti-inflammatory actions. By targeting neuroinflammatory mechanisms while offering meaningful metabolic benefits, MT1980 has the potential to address both negative symptoms and the high cardiometabolic burden experienced by people with schizophrenia.

Methods

Preclinical and pharmacokinetic and pharmacodynamic studies were conducted to characterise the CNS delivery and anti-inflammatory activity of MT1980 relative to standard formulations. These included assessment of systemic and brain exposure, as well as evaluation of neuroinflammatory cytokine modulation and microglial activation in an endotoxin-induced (LPS) neuroinflammation model. A Phase I clinical trial assessed safety, tolerability, pharmacokinetics, and measurement of MT1980 levels in cerebrospinal fluid. Planned next steps include a multiple-ascending-dose (MAD) study in healthy volunteers, and a proof-of-principle clinical study in schizophrenia patients with elevated inflammation and negative symptoms.

Results

MT1980 demonstrated improved systemic exposure and substantially enhanced brain penetration compared with standard formulations in preclinical studies. While both MT1980 and standard drug reduced peripheral inflammatory markers, only MT1980 significantly reduced inflammatory cytokine levels within brain tissue, consistent with effective central target engagement. Phase I studies showed excellent safety and tolerability, with evidence supporting CNS exposure. As a marketed lipid-modifying agent, MT1980 also offers established metabolic benefits, potentially providing a dual therapeutic opportunity in schizophrenia.

Conclusions

MT1980 addresses a key limitation of prior anti-inflammatory approaches in psychiatry by combining effective blood–brain barrier penetration with central anti-inflammatory activity and metabolic benefit. Through PPAR-α–mediated modulation of neuroinflammation and downstream effects on kynurenine pathway activity, MT1980 has the potential to influence signalling relevant to negative symptoms, and possibly positive and cognitive symptom domains. These data support further development of MT1980 for inflammation-associated schizophrenia. We discuss the design for a proof-of-principle clinical study to evaluate efficacy signals in patients with schizophrenia, incorporating inflammatory and pharmacodynamic biomarkers to assess target and predict treatment response.

References

No references